

Testicular cancer - new approaches in surgery and systemic treatment

Poster Session 82

Monday, 27 March
15:45 - 17:15

Location: Room Paris, North Hall (Level 1)

Chairs: M. Jewett, Toronto (CA)
D.L. Nicol, London (GB)
N. Nicolai, Milan (IT)

Aims and objectives of this session

This session will update the audience with new indications and outcome results from surgical approaches together with new systemic treatment options for patients with advanced germ cell cancer. In addition, quality of care issues will be discussed based on large registries.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

1084

Non-guideline concordant treatment of testicular cancer

By: [Paffenholz P.](#), Pfister D., Heidenreich A.

Institutes: University Hospital Cologne, Dept. of Urology, Cologne, Germany

*1085

Testicular cancer in patients with learning disabilities in England from 2001-2015: A national cohort study

By: Afshar M.², [Jackson-Spence E.](#)¹, De Santis M.³, Tanner J-R.⁴, Evison F.⁵, James N.³, Selby P.⁶, Patel P.⁷

Institutes:¹University of Birmingham, Medical School, Birmingham, United Kingdom, ²St George's University Hospitals NHS Foundation Trust, Dept. of Urological Oncology, London, United Kingdom, ³University of Warwick, Cancer Research Unit, Coventry, United Kingdom, ⁴University Hospitals Birmingham NHS Foundation Trust, Dept. of Oncology, Birmingham, United Kingdom, ⁵University Hospitals Birmingham NHS Foundation Trust, Dept. of Informatics, Birmingham, United Kingdom, ⁶University of Leeds, Leeds Institute of Cancer & Pathology, Leeds, United Kingdom, ⁷University of Birmingham, School of Cancer Sciences, Birmingham, United Kingdom

1086

Reliability of frozen section examination in a large cohort of testicular masses: What did we learn?

By: [Vartolomei M.D.](#)¹, Matei D.V.², Renne G.³, Tringali V.M.², Ferro M.², Bianchi R.², Russo A.², Cozzi G.², De Cobelli O.⁴

Institutes:¹University of Medicine and Pharmacy, Targu Mures, Romania and European Institute of Oncology, Dept. of Cell and Molecular Biology and Dept. of Urology, Milan, Italy, ²European Institute of Oncology, Dept. of Urology, Milan, Italy, ³European Institute of Oncology, Dept. of Pathology, Milan, Italy, ⁴European Institute of Oncology and University of Milan, Dept. of Urology, Milan, Italy

1087

Diagnostic value of frozen section examination (FSE) during inguinal exploration in patients with inconclusive testicular lesions

By: [Fankhauser C.](#)¹, Beyer J.², Roth L.¹, Sulser T.¹, Bode K-P.³, Moch H.³, Hermanns T.¹

Institutes:¹University Hospital Zurich, University of Zurich, Dept. of Urology, Zurich, Switzerland, ²University Hospital Zurich, University of Zurich, Dept. of Oncology, Zurich, Switzerland, ³University Hospital Zurich, University of Zurich, Dept. of Pathology and Molecular Pathology, Zurich, Switzerland

1088

Safety of testicular prosthesis insertion at the time of radical orchiectomy for testis cancer in patients undergoing adjuvant therapies

By: [Musi G.](#)¹, Cozzi G.¹, Bianchi R.¹, Mistretta F.A.¹, Tringali V.M.L.¹, Jereczeck B.A.², Nolé F.³, De

Cobelli O.¹

Institutes:¹European Institute of Oncology, Dept. of Urology, Milan, Italy, ²European Institute of Oncology, Dept. of Radiotherapy, Milan, Italy, ³European Institute of Oncology, Dept. of Oncology, Milan, Italy

1089

Laparoscopic retroperitoneal lymph-node dissection (L-RPLND) is not only a staging procedure in stage I non-seminomatous germ-cell testicular tumors (NSGCT): Mature data from a referral centre

By: Nicolai N.¹, Tarabelloni N.², Catanzaro M.¹, Gasperoni F.², Stagni S.¹, Torelli T.¹, Tesone A.¹, Kungulli A.¹, Necchi A.³, Giannatempo P.³, Raggi D.³, Colecchia M.⁴, Salvioni R.¹, Piva L.¹, Pizzocaro G.⁵, Biasoni D.¹

Institutes:¹Fondazione Irccs Istituto Nazionale Tumori, Dept. of Urology, Milan, Italy, ²Mox-Politecnico Di Milano, Dept. of Mathematics, Milan, Italy, ³Fondazione Irccs Istituto Nazionale Tumori, Dept. of Medical Oncology, Milan, Italy, ⁴Fondazione Irccs Istituto Nazionale Tumori, Dept. of Pathology, Milan, Italy, ⁵Fondazione Irccs Istituto Nazionale Tumori, Emeritus, Milan, Italy

1090

Primary retroperitoneal lymph node dissection (RPLND) in Stage II A/B seminoma patients without adjuvant treatment: A phase II trial (PRIMETEST)

By: Lusch A., Gerbaulet L., Winter C., Albers P.

Institutes:Düsseldorf University, Dept. of Urology, Düsseldorf, Germany

1091

Surgical resection of residual tumours after adjuvant chemotherapy of germ cell (GC) tumour

By: Gonzalez F.¹, Bossavy J-P.¹, Otal P.², Quintyn-Rant M-L.³, Roumigué M.⁴, Chevreau C.⁵, Malavaud B.⁴

Institutes:¹Chu Toulouse Rangueil, Dept. of Vascular Surgery, Toulouse, France, ²Chu Toulouse Rangueil, Dept. of Radiology, Toulouse, France, ³Institut Universitaire Du Cancer, Dept. of Pathology, Toulouse, France, ⁴Institut Universitaire Du Cancer, Dept. of Urology, Toulouse, France, ⁵Institut Universitaire Du Cancer, Dept. of Medical Oncology, Toulouse, France

1092

Complications and adjunctive surgical procedures in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) to define a tertial referral center

By: Lusch A., Gerbaulet L., Winter C., Albers P.

Institutes:Düsseldorf University, Dept. of Urology, Düsseldorf, Germany

1093

Bone metastases in germ cell tumours: Surgical management and outcomes

By: Nini A.¹, Konieczny M.², Winter C.³, Lusch A.³, Krauspe R.², Albers P.³

Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Dept. of Orthopedic Surgery, Düsseldorf, Germany, ³University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Dept. of Urology, Düsseldorf, Germany

1094

Retinal toxicity after cisplatin-based chemotherapy in patients with testicular cancer

By: Gild P.¹, Vetterlein M.¹, Dieckmann K.P.², Matthies C.³, Wagner W.³, Ludwig T.¹, Meyer C.¹, Soave A.¹, Dulz S.⁴, Asselborn N.⁴, Oechsle K.⁵, Bokemeyer C.⁵, Becker A.¹, Fisch M.¹, Hartmann M.¹, Chun F.¹, Kluth L.A.¹

Institutes:¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Albertinen Hospital, Dept. of Urology, Hamburg, Germany, ³Bundeswehr Medical Center Hamburg, Dept. of Urology, Hamburg, Germany, ⁴University Medical Center Hamburg-Eppendorf, Dept. of Ophthalmology, Hamburg, Germany, ⁵University Medical Center Hamburg-Eppendorf, Dept. of Medical Oncology, Hamburg, Germany

1095

The features and management of late relapse of non-seminomatous germ cell tumours

By: Jay A., Aldiwani M., Wijayarathna S., Huddart R., Mayer E., Nicol D.

Institutes:Royal Marsden Hospital, Dept. of Urology, Chelsea, United Kingdom

1096

Incidence of secondary malignancies (SM) in patients (pts) with germ cell tumors (GCT) who received high-dose chemotherapy (HDCT): A retrospective study from the European Society for Blood and Marrow Transplantation (EBMT) database

By: [Necchi A.](#)¹, Rosti G.², Badoglio M.³, Giannatempo P.⁴, Secondino S.², Lanza F.⁵, Pedrazzoli P.²
Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS Policlinico San Matteo, Dept. of Medical Oncology, Pavia, Italy, ³EBMT, EBMT Study Offices, Paris, France, ⁴Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ⁵Hospital of Ravenna, Dept. of Hematology, Ravenna, Italy

1097

Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase 2 Pazotest trial

By: [Necchi A.](#)¹, Lo Vullo S.², Giannatempo P.¹, Raggi D.¹, Calareso G.³, Togliardi E.⁴, Crippa F.⁵, Pennati M.⁶, Zaffaroni N.⁶, Perrone F.⁷, Colecchia M.⁷, Nicolai N.⁸, Mariani L.², Salvioni R.⁸

Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ³Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, ⁴Fondazione IRCCS - Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, ⁵Fondazione IRCCS - Istituto Nazionale Dei Tumori, Nuclear Medicine - PET Unit, Milan, Italy, ⁶Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Experimental Oncology and Molecular Medicine, Milan, Italy, ⁷Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy, ⁸Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy

17:06 - 17:15

Final comments

N. Nicolai, Milan (IT)